@gtbiopharmainc GT Biopharma Inc

GT Biopharma Inc posts on X about $gtbp, nasdaq, ceo, target the most. They currently have [--] followers and [--] posts still getting attention that total [--] engagements in the last [--] hours.

Engagements: undefined #

• [--] Week [---] +96%
• [--] Month [---] +261%

Mentions: undefined #

• [--] Month [--] +100%

Followers: [--] #

• [--] Week [--] no change
• [--] Month [--] +17%

CreatorRank: undefined #

Social Influence

Social category influence exchanges 95.24% finance 7.14% countries 4.76%

Social topic influence $gtbp 97.62%, nasdaq 95.24%, ceo 11.9%, target 11.9%, cell 7.14%, events 4.76%, the first 4.76%, bahamas 4.76%, safely 4.76%, science 4.76%

Top accounts mentioned or mentioned by @redchip @barchart

Top Social Posts

Top posts by engagements in the last [--] hours

"Were attending J.P. Morgan's 44th Annual Healthcare Conference in San Francisco next week. We look forward to engaging with industry leaders and investors as we advance our immunotherapies. Learn more about the event: #NASDAQ: $GTBP http://ordnl.link/fnx7X6Z http://ordnl.link/fnx7X6Z"
X Link 2026-01-15T14:00Z [--] followers, [---] engagements

"Our first 2nd-generation camelid nanobody TriKE GTB-3650 continues active enrollment in CD33-positive blood cancers. Early clinical data show NK cell activation & expansion a promising validation of our IL-15-enhanced NK cell engager technology"
X Link 2026-01-23T14:06Z [--] followers, [--] engagements

"For decades cancer care has relied on surgery radiation and chemotherapy. We're working to expand whats possible: developing immunotherapies intended to reduce toxicity and support more humane patient outcomes. Explore our mission: #NASDAQ: $GTBP http://ordnl.link/EQGZZnY http://ordnl.link/EQGZZnY"
X Link 2026-01-26T14:16Z [--] followers, [--] engagements

"TriKE molecules are compact modular NK cell engagers built to overcome limitations of CAR-T and monoclonal antibodies. At $GTBP we believe that they represent a next-generation platform for cancer and autoimmune diseases. Learn more: #NASDAQ http://ordnl.link/cCjjwZ4 http://ordnl.link/cCjjwZ4"
X Link 2026-01-28T14:11Z [--] followers, [---] engagements

"Get $GTBP s latest news delivered directly to your inbox from clinical advancements to corporate updates and upcoming events. Subscribe: #NASDAQ https://ir.gtbiopharma.com/email-alerts https://ir.gtbiopharma.com/email-alerts"
X Link 2026-01-30T15:27Z [--] followers, [---] engagements

"📢 NEWS RELEASE: The FDA has cleared our Investigational New Drug (IND) application for GTB-5550 our B7-H3-targeted NK cell engager for treating solid tumor #cancers.a We expect to begin Phase [--] clinical trials by mid-2026. Read more: #NASDAQ: $GTBP http://ordnl.link/HvwEHBV http://ordnl.link/HvwEHBV"
X Link 2026-02-03T14:13Z [--] followers, [---] engagements

"In this compelling episode of The Ellis Martin Report $GTBP CEO Michael Breen shares how the company stands at the forefront of a potential breakthrough in immuno-oncology that could redefine how we treat cancer & autoimmune diseases. Watch: #NASDAQ http://ordnl.link/KtfCxLy http://ordnl.link/KtfCxLy"
X Link 2026-02-10T14:26Z [--] followers, [--] engagements

"GTB-5550 combines NK cell activation survival support and tumor targeting in one therapy which may help the immune system recognize and attack B7-H3 expressing solid tumors more effectively. Read more: #NASDAQ: $GTBP http://ordnl.link/zj4hKWw http://ordnl.link/zj4hKWw"
X Link 2026-02-13T14:07Z [--] followers, [--] engagements

"GT Biopharmas 2nd gen TriKE platform is between [--] and [--] times more potent than the first generation driving a pipeline that spans AML/MDS solid tumors & autoimmune diseases. Several programs are in development or planned. Read: #NASDAQ: $GTBP https://www.gtbiopharma.com/product-pipeline/overview https://www.gtbiopharma.com/product-pipeline/overview"
X Link 2025-10-20T13:27Z [--] followers, [---] engagements

"TriKE is a first-in-class protein therapeutic platform that enhances NK cells natural ability to destroy cancer cells. It improves ADCC activation boosts NK cell persistence and reduces toxicities. Learn more: #NASDAQ: $GTBP http://asmbly.link/H2viij6 http://asmbly.link/H2viij6"
X Link 2025-10-22T14:03Z [--] followers, [---] engagements

"GTB-3650 is our first 2nd generation TriKE in a Phase [--] clinical trial targeting CD33-positive leukemias like AML & MDS. Patients in early cohorts have shown immune activity supporting NK cell expansion. Learn more: #NASDAQ: $GTBP http://asmbly.link/UfoZGk7 http://asmbly.link/UfoZGk7"
X Link 2025-10-24T13:00Z [--] followers, [---] engagements

"Just one day to go until the Centurion One Capital Bahamas Summit [----] at the Rosewood Baha Mar Well join global investors and small-cap growth companies to share our story insights and opportunities ahead. Join us: #NASDAQ: $GTBP http://asmbly.link/nBYUJ4g http://asmbly.link/nBYUJ4g"
X Link 2025-10-27T13:00Z [--] followers, [---] engagements

"GTB-5550 is being developed for B7H3+ solid tumors including breast lung ovarian prostate & more. Backed by preclinical data it will be our first TriKE tested with subcutaneous dosing & FDA submission is planned for Q4 [----]. Read: #NASDAQ: $GTBP http://asmbly.link/XvGLuwn http://asmbly.link/XvGLuwn"
X Link 2025-10-27T15:00Z [--] followers, [---] engagements

"The Centurion One Capital Bahamas Summit [----] kicks off today Were meeting with investors and peers to highlight our innovation & long-term growth strategy at one of the worlds leading small-cap events. Learn more: #NASDAQ: $GTBP http://asmbly.link/DdlPKkR http://asmbly.link/DdlPKkR"
X Link 2025-10-28T13:00Z [--] followers, [---] engagements

"Dr. Jeffrey Miller Professor at the University of Minnesota & Director of the Masonic Cancer Center has 20+ years in NK cell research with 170+ publications. He's a leader in advancing cancer immunotherapy. Our team: #NASDAQ: $GTBP http://asmbly.link/E7ujRHw http://asmbly.link/E7ujRHw"
X Link 2025-10-29T13:00Z [--] followers, [---] engagements

"GTB-7550 expands TriKE to new territory beyond #oncology. W/ activity shown in blood cancer models & research ongoing in autoimmune disease it represents the versatility of our rich & extensive platform. Learn about our product pipeline: #NASDAQ: $GTBP http://asmbly.link/zzEHzuV http://asmbly.link/zzEHzuV"
X Link 2025-10-31T13:00Z [--] followers, [---] engagements

"CEO Michael Breen discusses how our TriKE platform is designed to do what nature intended only stronger. It supercharges the bodys own immune system to identify target & destroy cancer cells while multiplying NK cells. Watch: #NASDAQ: $GTBP http://asmbly.link/6mT3uKv http://asmbly.link/6mT3uKv"
X Link 2025-11-04T14:24Z [--] followers, [---] engagements

"This #LungCancerAwarenessMonth we stand with patients and families worldwide. At GT Biopharma were developing NK cell therapies designed to empower the immune system to fight cancer safely and effectively. Visit: #NASDAQ: $GTBP http://asmbly.link/3QTet8h http://asmbly.link/3QTet8h"
X Link 2025-11-04T16:30Z [--] followers, [---] engagements

"Enrollment advances in our first-in-human Phase [--] trial for GTB-3650 in CD33-positive blood cancers. Cohort [--] completed with no safety or tolerability issues and Cohort [--] dosing is set to begin in the coming weeks. Read: #NASDAQ: $GTBP http://ordnl.link/otKopRy http://ordnl.link/otKopRy"
X Link 2025-11-07T15:18Z [--] followers, [---] engagements

"Our TriKE platform co-stimulates NK cells through CD16 and IL-15 producing a focused immune response with fewer side effects. It helps the bodys natural defenses target cancer precisely while protecting healthy cells. Learn more: #NASDAQ: $GTBP http://ordnl.link/Gh7qHtU http://ordnl.link/Gh7qHtU"
X Link 2025-11-10T14:00Z [--] followers, [---] engagements

"Our GTB-5550 TriKE is advancing toward FDA submission designed to target B7H3-positive solid tumors like breast lung ovarian pancreatic & prostate cancer. Its paving the way for more accessible patient-friendly immunotherapy. 🔗: $GTBP http://ordnl.link/dZMfCpJ http://ordnl.link/dZMfCpJ"
X Link 2025-11-12T14:00Z [--] followers, [---] engagements

"Our mission is clear: to develop more humane #cancer therapies. In this interview CEO Michael Breen explains our TriKE platform shares clinical progress on GTB-3650 and outlines what's ahead for our pipeline. Watch: #NASDAQ: $GTBP http://ordnl.link/xggSPp6 http://ordnl.link/xggSPp6"
X Link 2025-11-13T16:23Z [--] followers, [---] engagements

"With a growing clinical pipeline proof of concept in AML & cash runway into Q1 [----] we're advancing science that builds hope. Our mission is simple: to create safer more humane outcomes for those with cancer & autoimmune diseases. 🔗: #NASDAQ: $GTBP http://ordnl.link/FCrjrmr http://ordnl.link/FCrjrmr"
X Link 2025-11-17T14:02Z [--] followers, [--] engagements

"For [--] years cancer treatments have barely changed: surgery radiation chemotherapy. CEO Michael Breen shares how our TriKE platform harnesses the bodys own immune system to precisely target and destroy cancer cells. Watch: #NASDAQ: $GTBP http://ordnl.link/Z3dX5Jp http://ordnl.link/Z3dX5Jp"
X Link 2025-11-19T14:00Z [--] followers, [--] engagements

"GT Biopharma announces a corporate update and Q3 [----] financial results. Highlights include the continued progress in our Phase [--] clinical trial evaluating GTB-3650 in cancer patients along with our Q3 [----] financial summary. Read: #NASDAQ: $GTBP http://ordnl.link/qEgQu6T http://ordnl.link/qEgQu6T"
X Link 2025-11-19T16:18Z [--] followers, [---] engagements

"The global oncology market could grow from $139.4B in [----] to $268.3B by [----] as demand for targeted therapies grows. GT Biopharma is contributing to this space with its platform designed to harness NK cells against cancer. Read: #NASDAQ: $GTBP http://ordnl.link/wfkKhUa http://ordnl.link/wfkKhUa"
X Link 2025-11-20T14:00Z [--] followers, [---] engagements

"On #WorldPancreaticCancerDay we honor those affected by this devastating disease. Our TriKE platform is built to activate natural killer cells turning science into hope for a stronger more humane approach to cancer care. Visit: #NASDAQ: $GTBP http://ordnl.link/TAGWAO0 http://ordnl.link/TAGWAO0"
X Link 2025-11-20T18:17Z [--] followers, [---] engagements

"Our TriKE platform harnesses the bodys natural killer cells to fight cancer safely. Built with camelid & nanobody technology its a next-gen approach to #immunotherapy focused on precision safety & patient-centered outcomes. 🔗: #NASDAQ: $GTBP http://ordnl.link/okJquXR http://ordnl.link/okJquXR"
X Link 2025-11-24T14:21Z [--] followers, [---] engagements

"Executive Chairman and CEO Michael Breen explains the value that our Consulting Senior Medical Director Jeffrey S. Miller M.D. brings to GT Biopharma. 🎬 Full interview: #NASDAQ: $GTBP http://ordnl.link/aRngMYS http://ordnl.link/aRngMYS"
X Link 2025-11-27T14:10Z [--] followers, [--] engagements

"📩 Sign up to receive our latest news releases and clinical updates directly in your inbox. Stay informed as we advance our TriKE platform to deliver safer outcomes for those facing cancer & autoimmune disease. Subscribe: #NASDAQ: $GTBP http://ordnl.link/JdDeme5 http://ordnl.link/JdDeme5"
X Link 2025-11-28T14:00Z [--] followers, [--] engagements

"GTB-3650 is our first camelid and nanobody-based therapy in a first-in-human Phase [--] trial for AML and MDS. Its designed to activate NK cells and target cancer directly bringing patients closer to a more humane outcome. Read: #NASDAQ: $GTBP http://ordnl.link/CeATn6I http://ordnl.link/CeATn6I"
X Link 2025-12-01T14:00Z [--] followers, [--] engagements

"In October we completed a safety review for GTB-3650 with no issues reported in the 3rd dose group. This allows us to move ahead with the next group of patients and continue evaluating GTB-3650. Read: #NASDAQ: $GTBP http://ordnl.link/TeXjFVS http://ordnl.link/TeXjFVS"
X Link 2025-12-03T13:58Z [--] followers, [--] engagements

"In clinical trials our 1st-gen TriKE achieved bone marrow blast count reductions of 33% 60% 66% and 50% at higher dose levels. Pre-clinical studies show the 2nd generation is 10-40x more potent. Learn more: #NASDAQ: $GTBP http://ordnl.link/j6xRA5r http://ordnl.link/j6xRA5r"
X Link 2025-12-05T14:14Z [--] followers, [--] engagements

"From the first six patients treated in Cohorts [--] through [--] we have observed positive trends in immune-related biomarkers. These insights are helping guide dose escalation as GTB-3650 advances into Cohort [--]. Read: #NASDAQ: $GTBP http://ordnl.link/9rGNIBH http://ordnl.link/9rGNIBH"
X Link 2025-12-08T14:09Z [--] followers, [--] engagements

"GTB-5550 targets B7H3-positive solid tumors including breast lung ovarian and prostate cancer. Backed by preclinical data its our first TriKE planned for subcutaneous dosing making treatment simpler for patients. Read: #NASDAQ: $GTBP http://ordnl.link/iQVaUoj http://ordnl.link/iQVaUoj"
X Link 2025-12-10T14:00Z [--] followers, [--] engagements

"GTB-7550 is being developed for CD19-positive lymphoid cancers. Because it targets normal B cells it's also being explored for autoimmune disease with plans to begin manufacturing clinical material in 2026/7. More details: #NASDAQ: $GTBP http://ordnl.link/hgifSIX http://ordnl.link/hgifSIX"
X Link 2026-01-16T14:04Z [--] followers, [--] engagements

"By forming a direct link between NK cells and tumor cells and boosting natural killer cell activity with IL-15 TriKEs aim to strengthen the immune response. Discover: #NASDAQ: $GTBP http://ordnl.link/ApXD4SI http://ordnl.link/ApXD4SI"
X Link 2026-01-19T14:23Z [--] followers, [--] engagements

"NK cells are primed to kill cancer without prior sensitization. Our TriKE technology amplifies their natural power by strengthening the NKtumor cell connection and delivering IL-15 for in-body expansion. Learn more: #NASDAQ: $GTBP http://ordnl.link/yIIHQHJ http://ordnl.link/yIIHQHJ"
X Link 2026-01-20T14:14Z [--] followers, [--] engagements

"Our TriKE platform is built around a simple idea: activate the bodys own NK cells to fight cancer with precision and fewer side effects. Our therapies are designed to create safer more humane outcomes for patients. Learn more: #NASDAQ: $GTBP http://ordnl.link/t8Cdtdn http://ordnl.link/t8Cdtdn"
X Link 2026-01-21T14:03Z [--] followers, [--] engagements

"📢 Weve submitted an investigational new drug (IND) application to the U.S. FDA in December [----] for GTB-5550 TriKE a B7-H3-targeted natural killer (NK) cell engager for the treatment of B7-H3-expressing solid tumor cancers. Read: #NASDAQ: $GTBP http://ordnl.link/xrntoDx http://ordnl.link/xrntoDx"
X Link 2026-01-21T17:01Z [--] followers, [---] engagements

"TriKE molecules are engineered for favorable biodistribution a key consideration in solid tumor treatment. GTB-5550 is our first solid tumor TriKE moving toward clinical trial with planned subcutaneous dosing. Learn more: #NASDAQ: $GTBP http://ordnl.link/6BpSsGk http://ordnl.link/6BpSsGk"
X Link 2026-01-22T14:07Z [--] followers, [--] engagements

"More details: #NASDAQ: $GTBP http://ordnl.link/iT2Lvrf http://ordnl.link/iT2Lvrf"
X Link 2026-01-23T14:06Z [--] followers, [--] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing